Compare Vanguard Real Estate Index Fund ETF (VNQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Real Estate Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Real Estate Index Fund ETF trades at $97.36, while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| VNQ | WGS | |
|---|---|---|
52-Week High | $100.95 | $167.51 |
52-Week Low | $87.00 | $34.51 |
Market Cap | — | $2.44B |
Sector | — | Technology |
Enterprise Value | — | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNQ, the Vanguard Real Estate ETF, trades at $97.31, up 0.21% on the day, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The ETF's financial ratios are not disclosed in the provided data, limiting fundamental assessment. Recent news highlights institutional selling, with firms like City Holding Co. and Bank of America reducing positions, while media comparisons focus on VNQ's U.S. REIT exposure and low fees versus global alternatives.
Outlook remains cautious due to bearish technicals and institutional outflows, though the neutral oscillator reading and upcoming dividend in June 2026 offer some balance. Risks include interest rate sensitivity and real estate market volatility, but the ETF's low expense ratio and diversification provide a defensive income option for long-term investors amid economic uncertainty.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
